JP2022531347A5 - - Google Patents
Info
- Publication number
- JP2022531347A5 JP2022531347A5 JP2021564834A JP2021564834A JP2022531347A5 JP 2022531347 A5 JP2022531347 A5 JP 2022531347A5 JP 2021564834 A JP2021564834 A JP 2021564834A JP 2021564834 A JP2021564834 A JP 2021564834A JP 2022531347 A5 JP2022531347 A5 JP 2022531347A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- sequence
- composition according
- sgrna
- tracrrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000768A JP2024050582A (ja) | 2019-04-30 | 2024-01-05 | 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841046P | 2019-04-30 | 2019-04-30 | |
| US62/841,046 | 2019-04-30 | ||
| US201962897806P | 2019-09-09 | 2019-09-09 | |
| US62/897,806 | 2019-09-09 | ||
| US201962931630P | 2019-11-06 | 2019-11-06 | |
| US62/931,630 | 2019-11-06 | ||
| US202062959672P | 2020-01-10 | 2020-01-10 | |
| US62/959,672 | 2020-01-10 | ||
| US202062991285P | 2020-03-18 | 2020-03-18 | |
| US62/991,285 | 2020-03-18 | ||
| PCT/US2020/030782 WO2020223514A2 (en) | 2019-04-30 | 2020-04-30 | Novel omni-50 crispr nuclease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000768A Division JP2024050582A (ja) | 2019-04-30 | 2024-01-05 | 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022531347A JP2022531347A (ja) | 2022-07-06 |
| JP2022531347A5 true JP2022531347A5 (enExample) | 2023-05-11 |
Family
ID=73029467
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564834A Pending JP2022531347A (ja) | 2019-04-30 | 2020-04-30 | 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ |
| JP2024000768A Pending JP2024050582A (ja) | 2019-04-30 | 2024-01-05 | 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000768A Pending JP2024050582A (ja) | 2019-04-30 | 2024-01-05 | 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11666641B2 (enExample) |
| EP (1) | EP3963061A4 (enExample) |
| JP (2) | JP2022531347A (enExample) |
| KR (2) | KR102802134B1 (enExample) |
| CN (1) | CN114127274A (enExample) |
| AU (2) | AU2020266587B2 (enExample) |
| BR (1) | BR112021021912A2 (enExample) |
| CA (1) | CA3135759A1 (enExample) |
| IL (1) | IL287693A (enExample) |
| WO (1) | WO2020223514A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| JP2023531384A (ja) | 2020-06-04 | 2023-07-24 | エメンドバイオ・インコーポレイテッド | 新規なｏｍｎｉ－５９、６１、６７、７６、７９、８０、８１及び８２クリスパーヌクレアーゼ |
| CN116670271A (zh) * | 2020-11-04 | 2023-08-29 | 埃门多生物公司 | 新型omni-50 crispr核酸酶-rna复合物 |
| WO2022132765A1 (en) * | 2020-12-14 | 2022-06-23 | Emendobio Inc. | Biallelic knockout of b2m |
| EP4259159A4 (en) * | 2020-12-14 | 2025-04-09 | Emendobio Inc. | Biallelic knockout of trac |
| US12091688B2 (en) | 2021-02-08 | 2024-09-17 | Emendobio Inc. | OMNI-103 CRISPR nuclease |
| JP2024506608A (ja) | 2021-02-08 | 2024-02-14 | エメンドバイオ・インコーポレイテッド | Ｏｍｎｉ－１０３ ｃｒｉｓｐｒヌクレアーゼ |
| AU2022262623A1 (en) * | 2021-04-22 | 2023-11-30 | Emendobio Inc. | NOVEL OMNI 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 and 262 CRISPR NUCLEASES |
| IL310730A (en) * | 2021-08-12 | 2024-04-01 | Emendobio Inc | Engineered high fidelity omni-50 nuclease variants |
| CN118556119A (zh) * | 2021-11-19 | 2024-08-27 | 埃门多生物公司 | 新型omni crispr核酸酶 |
| CN118647715A (zh) * | 2021-12-01 | 2024-09-13 | 埃门多生物公司 | 工程化高活性omni-79核酸酶变体 |
| AU2023308345A1 (en) * | 2022-07-15 | 2025-02-27 | Emendobio Inc. | Strategies for knock-ins at aplp2 safe harbor sites |
| WO2024042165A2 (en) * | 2022-08-26 | 2024-02-29 | UCB Biopharma SRL | Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases |
| WO2025043140A1 (en) * | 2023-08-23 | 2025-02-27 | Emendobio Inc. | Methods and compositions for modifying expression of a mutant transforming growth factor beta induced (tgfbi) allele |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383604B2 (en) | 2008-09-15 | 2013-02-26 | Children's Medical Center Corporation | Modulation of BCL11A for treatment of hemoglobinopathies |
| AU2013266968B2 (en) * | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| US11028388B2 (en) * | 2014-03-05 | 2021-06-08 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa |
| WO2017024047A1 (en) | 2015-08-03 | 2017-02-09 | Emendobio Inc. | Compositions and methods for increasing nuclease induced recombination rate in cells |
| US12043843B2 (en) | 2015-11-04 | 2024-07-23 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
| CN105567735A (zh) * | 2016-01-05 | 2016-05-11 | 华东师范大学 | 一种凝血因子基因突变的定点修复载体系统及方法 |
-
2020
- 2020-04-30 BR BR112021021912A patent/BR112021021912A2/pt unknown
- 2020-04-30 KR KR1020217037743A patent/KR102802134B1/ko active Active
- 2020-04-30 EP EP20799462.5A patent/EP3963061A4/en active Pending
- 2020-04-30 KR KR1020257013727A patent/KR20250060327A/ko active Pending
- 2020-04-30 CN CN202080032631.5A patent/CN114127274A/zh active Pending
- 2020-04-30 CA CA3135759A patent/CA3135759A1/en active Pending
- 2020-04-30 JP JP2021564834A patent/JP2022531347A/ja active Pending
- 2020-04-30 US US17/594,761 patent/US11666641B2/en active Active
- 2020-04-30 AU AU2020266587A patent/AU2020266587B2/en active Active
- 2020-04-30 WO PCT/US2020/030782 patent/WO2020223514A2/en not_active Ceased
-
2021
- 2021-10-28 IL IL287693A patent/IL287693A/en unknown
-
2023
- 2023-04-06 US US18/296,798 patent/US20240226246A9/en active Pending
-
2024
- 2024-01-05 JP JP2024000768A patent/JP2024050582A/ja active Pending
- 2024-04-04 AU AU2024202171A patent/AU2024202171A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531347A5 (enExample) | ||
| CN105238806B (zh) | 一种用于微生物的CRISPR/Cas9基因编辑载体的构建及其应用 | |
| KR102595683B1 (ko) | 변형된 가이드 rna | |
| JP2021118726A5 (enExample) | ||
| JP2022520428A5 (enExample) | ||
| JP2021530988A5 (enExample) | ||
| US20150291961A1 (en) | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX | |
| FI4118198T3 (fi) | Rna-ohjattuja nukleaaseja ja niiden aktiivisia fragmentteja ja variantteja ja käyttömenetelmiä | |
| IL288263B (en) | CRISPR DNA/RNA hybrid polynucleotides and methods of using them | |
| WO2021023307A1 (zh) | CRISPR/Cas9基因编辑系统及其应用 | |
| JPH07507201A (ja) | 可変鋳型反応 | |
| CN103911376A (zh) | CRISPR-Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA | |
| JP2023508731A5 (enExample) | ||
| CN110577971B (zh) | CRISPR/Sa-SauriCas9基因编辑系统及其应用 | |
| Khan et al. | CRISPR/dCas9-mediated inhibition of replication of begomoviruses. | |
| CN117568348B (zh) | 用于维持多聚腺苷质粒单体超螺旋的基因及其应用 | |
| US20220389418A1 (en) | Rna-guided cas nucleases and uses thereof in diagnostics and therapy | |
| CA3225082A1 (en) | Enzymes with ruvc domains | |
| WO2023206872A1 (zh) | 一种工程优化的核酸酶、向导rna、编辑系统和应用 | |
| CN106282173B (zh) | 克隆转基因生物中外源基因整合位点处侧翼序列的方法 | |
| JP2024545144A5 (enExample) | ||
| CN119193713A (zh) | 修饰的双链供体模板 | |
| CN105602972B (zh) | 基于CRISPR-Cas9体外改造腺病毒载体的方法 | |
| CN110551761A (zh) | CRISPR/Sa-SepCas9基因编辑系统及其应用 | |
| CN110551760B (zh) | CRISPR/Sa-SeqCas9基因编辑系统及其应用 |